Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer

Molecular and Cellular Proteomics

Volumn 13, Issue 11, 2014, Pages 3082-3096

  Nazarian, Arpi ^a   Lawlor, Kevin ^a   Yi, San San ^a   Philip, John ^a   Ghosh, Mousumi ^a,e   Yaneva, Mariana ^a   Villanueva, Josep ^a,f   Saghatelian, Alan ^b   Assel, Melissa ^a   Vickers, Andrew J ^a   Eastham, James A ^a   Scher, Howard I ^a   Carver, Brett S ^a   Lilja, Hans ^a,c,d   Tempst, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e YALE UNIVERSITY   (United States)

^f VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; AMINOPEPTIDASE; DPP4 PROTEIN, HUMAN; DPP4 PROTEIN, MOUSE; MYC PROTEIN; MYC PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PTEN PROTEIN, MOUSE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CHEMICAL ANALYSIS; CHROMOSOME INSERTION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTATIC PROSTATE CANCER; MOUSE; NONHUMAN; ONCOGENE C MYC; PENETRANCE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEGRADATION; REACTION TIME; ANIMAL; BIOSYNTHESIS; BLOOD; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS;

AMINOPEPTIDASES; ANIMALS; BIOMARKERS, TUMOR; DIPEPTIDYL PEPTIDASE 4; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84909600448     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M114.038836     Document Type: Article

References (72)

1. Rifai, N., Gillette, M. A., and Carr, S. A. (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971-983
2. Ransohoff, D. F. (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 60, 1205-1219
3. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174
4. Matrisian, L. M., Sledge, G. W., Jr., and Mohla, S. (2003) Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 63, 6105-6109
5. Lopez-Otin, C., and Matrisian, L. M. (2007) Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808
6. Palermo, C., and Joyce, J. A. (2008) Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 29, 22-28
7. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A., Erdjument-Bromage, H., Olshen, A. B., Fleisher, M., Lilja, H., Brogi, E., Boyd, J., Sanchez-Carbayo, M., Holland, E. C., Cordon-Cardo, C., Scher, H. I., and Tempst, P. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271-284
8. Villanueva, J., Nazarian, A., Lawlor, K., Yi, S. S., Robbins, R. J., and Tempst, P. (2008) A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol. Cell. Proteomics 7, 509-518
9. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y., Toledo-Crow, R., DeNoyer, L., Fleisher, M., Robbins, R. J., and Tempst, P. (2005) Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 4, 1060-1072
10. Check, E. (2004) Proteomics and cancer: running before we can walk? Nature 429, 496-497
11. Diamandis, E. P. (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3, 367-378
12. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M. J. (2007) Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66
13. Albertsen, P. C. (2010) Treatment of localized prostate cancer: when is active surveillance appropriate? Nat. Rev. Clin. Oncol. 7, 394-400
14. Rathkopf, D., and Scher, H. I. (2013) Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 19, 43-49
15. Shariat, S. F., Semjonow, A., Lilja, H., Savage, C., Vickers, A. J., and Bjartell, A. (2011) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 50 Suppl 1, 61-75
16. Lilja, H., Cronin, A. M., Dahlin, A., Manjer, J., Nilsson, P. M., Eastham, J. A., Bjartell, A. S., Scardino, P. T., Ulmert, D., and Vickers, A. J. (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117, 1210-1219
17. Vickers, A. J., Roobol, M. J., and Lilja, H. (2012) Screening for prostate cancer: early detection or overdetection? Annu. Rev. Med. 63, 161-170
18. Fradet, Y. (2009) Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr. Opin. Urol. 19, 243-246
19. Scher, H. I., and Heller, G. (2000) Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55, 323-327
20. Smaletz, O., Scher, H. I., Small, E. J., Verbel, D. A., McMillan, A., Regan, K., Kelly, W. K., and Kattan, M. W. (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol. 20, 3972-3982
21. Bianco, F. J., Jr. (2008) Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. Urol. Oncol. 26, 408-414
22. Villanueva, J., Nazarian, A., Lawlor, K., and Tempst, P. (2009) Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat. Protoc. 4, 1167-1183
23. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A., Tanwar, M. K., Holland, E. C., and Tempst, P. (2004) Serum peptide profiling by magnetic particle-Assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560-1570
24. Villanueva, J., Lawlor, K., Toledo-Crow, R., and Tempst, P. (2006) Automated serum peptide profiling. Nat. Protoc. 1, 880-891
25. Villanueva, J., Philip, J., DeNoyer, L., and Tempst, P. (2007) Data analysis of assorted serum peptidome profiles. Nat. Protoc. 2, 588-602
26. Mitrunen, K., Pettersson, K., Piironen, T., Bjork, T., Lilja, H., and Lovgren, T. (1995) Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin. Chem. 41, 1115-1120
27. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., and Sawyers, C. L. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238
28. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., Cordon-Cardo, C., and Pandolfi, P. P. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730
29. Durinx, C., Neels, H., Van der Auwera, J. C., Naelaerts, K., Scharpe, S., and De Meester, I. (2001) Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clin. Chem. Lab. Med. 39, 155-159
30. Leiting, B., Pryor, K. D., Wu, J. K., Marsilio, F., Patel, R. A., Craik, C. S., Ellman, J. A., Cummings, R. T., and Thornberry, N. A. (2003) Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. 371, 525-532
31. Barrett, A. J., Rawlings, N. D., and Woessner, J. F. (2004) Handbook of Proteolytic Enzymes, 2nd ed., Elsvier Academic Press, Amsterdam, The Netherlands
32. Farrah, T., Deutsch, E. W., Omenn, G. S., Campbell, D. S., Sun, Z., Bletz, J. A., Mallick, P., Katz, J. E., Malmstrom, J., Ossola, R., Watts, J. D., Lin, B., Zhang, H., Moritz, R. L., and Aebersold, R. (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 10, M110.006353
33. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A. M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., and Wagtmann, N. (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 97, 6874-6879
34. Tagore, D. M., Nolte, W. M., Neveu, J. M., Rangel, R., Guzman-Rojas, L., Pasqualini, R., Arap, W., Lane, W. S., and Saghatelian, A. (2009) Peptidase substrates via global peptide profiling. Nat. Chem. Biol. 5, 23-25
35. Thornberry, N. A., and Weber, A. E. (2007) Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem. 7, 557-568
36. DeClerck, Y. A., Mercurio, A. M., Stack, M. S., Chapman, H. A., Zutter, M. M., Muschel, R. J., Raz, A., Matrisian, L. M., Sloane, B. F., Noel, A., Hendrix, M. J., Coussens, L., and Padarathsingh, M. (2004) Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 164, 1131-1139
37. Puente, X. S., Sanchez, L. M., Overall, C. M., and Lopez-Otin, C. (2003) Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4, 544-558
38. Cordero, O. J., Salgado, F. J., and Nogueira, M. (2009) On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 58, 1723-1747
39. De Meester, I., Scharpe, S., and Lambeir, A. M. (2009) Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets. Clin. Chem. Lab. Med. 47, 245-247
40. Matheeussen, V., Baerts, L., De Meyer, G., De Keulenaer, G., Van der Veken, P., Augustyns, K., Dubois, V., Scharpe, S., and De Meester, I. (2011) Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol. Chem. 392, 189-198
41. De Meester, I., Vanhoof, G., Hendriks, D., Demuth, H. U., Yaron, A., and Scharpe, S. (1992) Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin. Chim. Acta 210, 23-34
42. Durinx, C., Lambeir, A. M., Bosmans, E., Falmagne, J. B., Berghmans, R., Haemers, A., Scharpe, S., and De Meester, I. (2000) Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur. J. Biochem. 267, 5608-5613
43. Pro, B., and Dang, N. H. (2004) CD26/dipeptidyl peptidase IV and its role in cancer. Histol. Histopathol. 19, 1345-1351
44. Brandt, I., Lambeir, A. M., Maes, M. B., Scharpe, S., and De Meester, I. (2006) Peptide substrates of dipeptidyl peptidases. Adv. Exp. Med. Biol. 575, 3-18
45. Lambeir, A. M., Scharpe, S., and De Meester, I. (2008) DPP4 inhibitors for diabetes-what next? Biochem. Pharmacol. 76, 1637-1643
46. Hino, M., Nagatsu, T., Kakumu, S., Okuyama, S., Yoshii, Y., and Nagatsu, I. (1975) Glycylprolyl beta-naphthylamidase activity in human serum. Clin. Chim. Acta 62, 5-11
47. Haacke, W., Kullertz, G., and Barth, A. (1986) [Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers]. Arch. Geschwulstforsch. 56, 145-153
48. Kojima, J., Ueno, Y., Kasugai, H., Okuda, S., and Akedo, H. (1987) Glycylproline dipeptidyl aminopeptidase and gamma-glutamyl transpeptidase in human hepatic cancer and embryonal tissues. Clin. Chim. Acta 167, 285-291
49. Kojima, K., Mihara, R., Sakai, T., Togari, A., Matsui, T., Shinpo, K., Fujita, K., Fukasawa, K., Harada, M., and Nagatsu, T. (1987) Serum activities of dipeptidyl-Aminopeptidase II and dipeptidyl-Aminopeptidase IV in tumorbearing animals and in cancer patients. Biochem. Med. Metab. Biol. 37, 35-41
50. Bogenrieder, T., Finstad, C. L., Freeman, R. H., Papandreou, C. N., Scher, H. I., Albino, A. P., Reuter, V. E., and Nanus, D. M. (1997) Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 33, 225-232
51. Cordero, O. J., Ayude, D., Nogueira, M., Rodriguez-Berrocal, F. J., and de la Cadena, M. P. (2000) Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br. J. Cancer 83, 1139-1146
52. Javidroozi, M., Zucker, S., and Chen, W. T. (2012) Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer. Dis. Markers 32, 309-320
53. Kotackova, L., Balaziova, E., and Sedo, A. (2009) Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia Biol. 55, 77-84
54. Sedo, A., Stremenova, J., Busek, P., and Duke-Cohan, J. S. (2008) Dipeptidyl peptidase-IV and related molecules: markers of malignancy? Expert Opin. Med. Diagn. 2, 677-689
55. Dinjens, W. N., Ten Kate, J., Kirch, J. A., Tanke, H. J., Van der Linden, E. P., Van den Ingh, H. F., Van Steenbrugge, G. J., Meera Khan, P., and Bosman, F. T. (1990) Adenosine deaminase complexing protein (ADCP) expression and metastatic potential in prostatic adenocarcinomas. J. Pathol. 160, 195-201
56. Smith, R. E., Talhouk, J. W., Brown, E. E., and Edgar, S. E. (1998) The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding. AIDS Res. Hum. Retroviruses 14, 851-868
57. Cuchacovich, M., Gatica, H., Pizzo, S. V., and Gonzalez-Gronow, M. (2001) Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin. Exp. Rheumatol. 19, 673-680
58. Christopherson, K. W., 2nd, Hangoc, G., Mantel, C. R., and Broxmeyer, H. E. (2004) Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305, 1000-1003
59. Passaniti, A., and Hart, G. W. (1988) Cell surface sialylation and tumor metastasis. Metastatic potential of B16 melanoma variants correlates with their relative numbers of specific penultimate oligosaccharide structures. J. Biol. Chem. 263, 7591-7603
60. Davoodi, J., Kelly, J., Gendron, N. H., and MacKenzie, A. E. (2007) The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics 7, 2300-2310
61. Pilia, G., Hughes-Benzie, R. M., MacKenzie, A., Baybayan, P., Chen, E. Y., Huber, R., Neri, G., Cao, A., Forabosco, A., and Schlessinger, D. (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet. 12, 241-247
62. Chen, M., Li, G., Yan, J., Lu, X., Cui, J., Ni, Z., Cheng, W., Qian, G., Zhang, J., and Tu, H. (2013) Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin. Chim. Acta 423, 105-111
63. Zhang, L., Liu, H., Sun, L., Li, N., Ding, H., and Zheng, J. (2012) Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem. 114, 547-552
64. Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N., Landers, T., Dolgalev, I., Major, J. E., Wilson, M., Socci, N. D., Lash, A. E., Heguy, A., Eastham, J. A., Scher, H. I., Reuter, V. E., Scardino, P. T., Sander, C., Sawyers, C. L., and Gerald, W. L. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22
65. Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., and Schultz, N. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1
66. Wesley, U. V., Albino, A. P., Tiwari, S., and Houghton, A. N. (1999) A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J. Exp. Med. 190, 311-322
67. Wesley, U. V., Tiwari, S., and Houghton, A. N. (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int. J. Cancer 109, 855-866
68. Kikkawa, F., Kajiyama, H., Shibata, K., Ino, K., Nomura, S., and Mizutani, S. (2005) Dipeptidyl peptidase IV in tumor progression. Biochim. Biophys. Acta 1751, 45-51
69. Havre, P. A., Abe, M., Urasaki, Y., Ohnuma, K., Morimoto, C., and Dang, N. H. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 13, 1634-1645
70. Masur, K., Schwartz, F., Entschladen, F., Niggemann, B., and Zaenker, K. S. (2006) DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul. Pept. 137, 147-155
71. Wesley, U. V., McGroarty, M., and Homoyouni, A. (2005) Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 65, 1325-1334
72. Sun, Y. X., Pedersen, E. A., Shiozawa, Y., Havens, A. M., Jung, Y., Wang, J., Pienta, K. J., and Taichman, R. S. (2008) CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin. Exp. Metastasis 25, 765-776